2010-02-01
Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia
Publication
Publication
Leukemia Research: clinical and laboratory studies , Volume 34 - Issue 2 p. 154- 159
Introduction: Impaired motor performance in children who completed treatment for acute lymphoblastic leukemia (ALL) may be related to polymorphisms of the metabolising gene CYP3A5 or vincristine toxicity related genes MDR-1 and MAPT. Methods: Motor performance was measured with the Movement Assessment Battery for Children (movement-ABC). DNA, from mononuclear blood cells was genotyped for CYP3A5, MDR-1 and MAPT polymorphisms. Results: Motor performance was not significantly affected by CYP3A5 *3/*3 and CYP3A5*1*3 genotypes, MDR-1 polymorphisms or MAPT haplotype. Conclusion: Our data did not show that CYP3A5, MDR-1 or MAPT polymorphisms are linked to impaired motor performance in children after treatment for ALL.
| Additional Metadata | |
|---|---|
| , , | |
| doi.org/10.1016/j.leukres.2009.04.027, hdl.handle.net/1765/27735 | |
| Leukemia Research: clinical and laboratory studies | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
Hartman, A., van Schaik, R., van der Heiden, I., Broekhuis, M., Meier, M., den Boer, M., & Pieters, R. (2010). Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia. Leukemia Research: clinical and laboratory studies, 34(2), 154–159. doi:10.1016/j.leukres.2009.04.027 |
|